A review of the new angiotensin II receptor antagonist irbesartan

被引：16
|
作者：
Powell, JR
Reeves, RA
Marino, MR
Cazaubon, C
Nisato, D
机构：
[1] Bristol Myers Squibb, Cardiovasc Drug Discovery, Princeton, NJ 08543 USA
[2] Sanofi Rech, Dept Cardiovasc Res, F-34082 Montpellier, France
来源：
CARDIOVASCULAR DRUG REVIEWS | 1998年 / 16卷 / 03期
关键词：
angiotensin II (AT(1)) receptor antagonist; hypertension; irbesartan;
D O I：
10.1111/j.1527-3466.1998.tb00354.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Irbesartan is a novel, noncompetitive, insurmountable AIIRA specific for the AT1 receptor subtype. When administered orally, it is readily bioavailable and its absorption is not affected by food. Its long elimination half-life allows for once-daily dosing. Irbesartan does not rely on active metabolites for antihypertensive activity, and is eliminated by hepatic and renal routes. Once-daily irbesartan effectively lowers BP in a dose-dependent manner in animals and humans. Blood pressure reductions last for the entire 24-h dosing interval in humans. Irbesartan has a placebo-like safety profile at all dose levels and is well tolerated in patients with hypertension.
引用
收藏
页码：169 / 194
页数：26
相关论文
共 50 条
  • [1] A review of the clinical experience with the angiotensin II receptor antagonist irbesartan
    Waeber, B
    CARDIOVASCULAR DRUG REVIEWS, 2000, 18 (02): : 103 - 126
  • [2] Clinical overview of irbesartan - A new angiotensin II receptor antagonist
    Pouleur, HG
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) : 318S - 324S
  • [3] The new angiotensin II receptor antagonist, irbesartan - Pharmacokinetic and pharmacodynamic considerations
    Brunner, HR
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) : 311S - 317S
  • [4] Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist
    Ruilope, L
    JOURNAL OF HYPERTENSION, 1997, 15 : S15 - S20
  • [5] Angiotensin II receptor antagonist irbesartan in the treatment of chronic heart failure
    Belousov, YB
    Upnitsky, AA
    Khanina, NY
    KARDIOLOGIYA, 2000, 40 (10) : 88 - 91
  • [6] Review of eprosartan: A new angiotensin II receptor antagonist - Summary
    Sica, DA
    PHARMACOTHERAPY, 1999, 19 (04): : 108S - 109S
  • [7] Review of eprosartan: A new angiotensin II receptor antagonist - Introduction
    Hollenberg, NK
    PHARMACOTHERAPY, 1999, 19 (04): : 71S - 72S
  • [8] Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension
    Debernardi-Venon, W
    Barletti, C
    Alessandria, C
    Marzano, A
    Baronio, M
    Todros, L
    Saracco, G
    Repici, A
    Rizzetto, M
    DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (02) : 401 - 404
  • [9] Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease
    von Vigier, RO
    Zberg, PM
    Teuffel, O
    Bianchetti, MG
    EUROPEAN JOURNAL OF PEDIATRICS, 2000, 159 (08) : 590 - 593
  • [10] Effects of the angiotensin II receptor antagonist irbesartan on the endothelial function in patients with hypertension
    Koval, SN
    Mysnichenko, OV
    Maslyaeva, LV
    Starchenko, TG
    JOURNAL OF HYPERTENSION, 2000, 18 : S156 - S156
12345